Celea Therapeutics secures $180m for Phase III SURPASS-IPF trial

Celea Therapeutics has secured $180m in financing to support the planned pivotal Phase III SURPASS-IPF clinical trial of deupirfenidone. The trial is expected to begin in early third quarter of 2026. IPF is a rare, progressive and fatal disease marked by irreversible lung scarring and declining lung function. Credit: SkazovD/Shutterstock.com. Celea Therapeutics has secured $180m in financing to support the planned pivotal Phase III SURPASS-IPF clinical trial of deupirfenidone (LYT-100). Deupirfenidone is an investigational next-generation antifibrotic and has the potential to serve as a new standard of care for individuals with idiopathic pulmonary fibrosis (IPF). LOA and PTSR Model -…

Source: Clinical Trials Arena